Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 4/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.53 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370195 | 0.93 | MOGAT2 (0.51) | MOGAT2LRRK2BRD4MGAT2PAK1 | |
| SCHEMBL5366406 | 0.91 | MOGAT2 (0.55) | MOGAT2LRRK2BRD4MGAT2PRKDC | |
| SCHEMBL7139561 | 0.91 | MOGAT2 (0.56) | MOGAT2LRRK2BRD4MGAT2PRKDC | |
| SCHEMBL7140002 | 0.90 | MOGAT2 (0.56) | MOGAT2LRRK2MGAT2PRKDCMEN1 | |
| SCHEMBL5369240 | 0.89 | LRRK2 (0.57) | MOGAT2LRRK2BRD4MGAT2PRKDC | |
| SCHEMBL5357751 | 0.89 | MOGAT2 (0.55) | MOGAT2LRRK2BRD4MGAT2PRKDC | |
| SCHEMBL5363184 | 0.88 | EGFR (0.58) | MOGAT2LRRK2BRD4MGAT2PRKDC | |
| SCHEMBL5358368 | 0.88 | MOGAT2 (0.61) | MOGAT2LRRK2MGAT2MEN1ALOX15 | |
| SCHEMBL5361301 | 0.88 | MOGAT2 (0.56) | MOGAT2LRRK2MGAT2 | |
| SCHEMBL7137576 | 0.87 | MOGAT2 (0.57) | MOGAT2LRRK2MGAT2PRKDCMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | MOGAT2 1159/4885LRRK2 289/4885BRD4 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.